Back to Hematology
Hematologyv2012Evidence-Based

DASH Prediction Score for Recurrent VTE

Predicts likelihood of recurrence of first unprovoked venous thromboembolism (VTE) to guide anticoagulation duration decisions. Utilizes D-dimer, Age, Sex, and Hormonal therapy factors.

Clinical Input Parameters

years
Range: 18 — 100 years
months
Range: 3 — 24 months
Clinical Assessment
Awaiting Parameters
dash assessment
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The DASH Prediction Score for Recurrent VTE is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

DASH Score = (+2 if D-dimer positive) + (+1 if age ≤50 years) + (+1 if male) + (-2 if hormonal therapy in women)

Clinical Pearls & Practice Notes

  • Score applies only to patients with first unprovoked VTE
  • D-dimer measured approximately 1 month after stopping anticoagulation
  • Hormonal therapy scoring applies only to women (birth control, HRT)
  • Excludes VTE during pregnancy, puerperium, trauma, surgery, immobilization, or active cancer
  • Original validation used vitamin K antagonists
  • External validation showed higher recurrence risk in patients >65 years even with low DASH scores
  • Should be used in conjunction with bleeding risk assessment
  • Tool aids in shared decision-making but does not replace clinical judgment
  • Regular reassessment recommended as patient factors may change over time

Evidence & Literature Citations

  1. Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10(6):1019-1025. doi: 10.1111/j.1538-7836.2012.04735.x.
  2. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.
  3. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738. doi: 10.1182/bloodadvances.2020001830.
  4. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630-1636. doi: 10.1161/CIRCULATIONAHA.109.925214.

Score Interpretation Ranges

Low Risk-2 – 1 pts

Low annual recurrence risk

Intermediate Risk2 – 2 pts

Moderate annual recurrence risk

High Risk3 – 6 pts

High annual recurrence risk

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.